Summary
The serum protein binding of maprotiline and phenytoin has been compared in a group of 22 uraemic patients receiving haemodialysis. Determination of protein binding was carried out in vitro using equilibrium dialysis at 37°C and14C-labelled drug. The mean percentage unbound maprotiline found in patients (10.0%, SD 2.5) was not significantly different from that obtained in healthy volunteers (mean 10.5%, SD 1.0). However, there was a significantly increased variability in binding in patients compared with healthy subjects. The mean percentage unbound phenytoin in the same patients (22.2%, SD 3.3) was significantly greater than that obtained in healthy control subjects (12.5%, SD 0.6). Although there was no correlation between maprotiline and phenytoin binding and serum concentrations of α1-acid glycoprotein, there was a significant correlation between percentage unbound maprotiline and serum albumin concentrations. The findings indicate that the binding of this tricyclic antidepressant is essentially normal in uraemia, although there may be increased interindividual variability in the free fraction of drug.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Reidenberg MM (1977) The binding of drugs to plasma proteins and the interpretation of measurements of plasma concentrations of drugs in patients with poor renal function. Am J Med 62: 466–470
Reidenberg MM, Odar-Cederlöf I, von Bahr C, Borga O, Sjöqvist F (1971) Protein binding of diphenylhydantoin and desmethylimipramine in plasma from patients with poor-renal function. N Engl J Med 285: 264–267
Rosser RA, Braithwaite RA, Dawling S, Lynn KL (1979) Antidepressives in renal failure. In: Obiols J, Monclus EG, Pujol J (eds) Biological psychiatry today. Elsevier North Holland Biomedical Press, Amsterdam, pp 985–990
Ernebo M, Agurell S, Jalling B, Boreus LO (1971) Age differences in drug binding by plasma proteins: studies on human fetuses, neonates and adults. Eur J Clin Pharmacol 3: 189–193
Reiss W, Dubey L, Fünfgeld EW, Imhof P, Hurzeler H, Matussek N, Rajagopalan TG, Raschdorf F, Schmid K (1975) The pharmacokinetic properties of maprotiline (Ludiomil) in man. J Int Med Res 3: 16–41
Shoeman DW, Azarnoff DL (1972) The alteration of plasma proteins in uraemia as reflected in their ability to bind digitoxin and diphenylhydantoin. Pharmacology 7: 169–177
Hooper WD, Bochner F, Eadie MJ, Tyrer JH (1974) Plasma protein binding of diphenylhydantoin. Effects of sex hormones, renal and hepatic disease. Clin Pharmacol Ther 15: 276–282
Piafsky KM, Borga O, Odar-Cederlöf I, Johansson C, Sjöqvist F (1978) Increased plasma protein binding of propranolol and chlorpromazine mediated by disease induced elevation of α1-acid glycoprotein. N Engl J Med 299: 1435–1439
Piafsky KM, Borga O (1977) Plasma protein binding of basic drugs. Il Importance of α1-acid glycoprotein for interindividual variation. Clin Pharmacol Ther 22: 545–549
Schmid K (1975) α1-acid glycoprotein. In: Putman FW (ed) The plasma proteins, vol 1. Academic Press, New York, pp 187–228
Braithwaite RA, Heard R, Snape A (1978) Plasma protein binding of maprotiline in geriatric patients — influence of α1-acid glycoprotein. Br J Clin Pharmacol 6: 448–449
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Lynn, K., Braithwaite, R., Dawling, S. et al. Comparison of the serum protein binding of maprotiline and phenytoin in uraemic patients on haemodialysis. Eur J Clin Pharmacol 19, 73–77 (1981). https://doi.org/10.1007/BF00558388
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00558388